This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Anticitrulline antibodies (anti-CCP)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • antibodies to citrullinated proteins that show great specificity for rheumatoid arthritis (RA) and have the potential to indicate which patients are likely to have destructive joint disease (1)
    • citrulline is the product of post-translational modification of protein-bound arginine, catalysed by peptidylarginine deiminase (PAD)
      • there is a high specificity of antibodies to citrullinated proteins for RA - also an association to RA related joint damage
      • as well as occurring during the terminal differentiation of keratinocytes, citrullination occurs during cell death and injury
      • a reproducible and readily available assay has been developed to detect antibodies (anticyclic citrullinated peptide - anti-CCP)
      • anti-CCP antibodies are produced locally within the joint of RA patients
  • use in RA
    • a very high proportion of patients with established RA have (predominately IgG) anti-CCP antibodies - up to 80% with RA are positive for anti-CCP. This compares with to finding anti-CCP in only 2-5% disease controls and 0-1% healthy controls
      • anti-CCP antibodies appear early in RA and can predate the clinical onset of disease by years - most, but not all, patients are also positive for RF
      • anti-CCP is associated with joint damage - this is the case even in those patients who are RF-negative. However anti-CCP is not associated with extraarticular features (unlike RF)
      • variation of levels with treatment of RA
        • the titre of anti-CCP does not fall with 'standard' anti-rheumatic therapy (unlike RF). There have however been reported significant falls in patients clinically responding to infliximab and to rituximab
      • anti-CCP has been reported to help distinguish between polymyalgia rheumatica and a polymyalgic onset of RA in elderly people
      • in children, anti-CCP has been reported in 13% of children with polyarticular juvenile idiopathic arthritis (JIA) (with an association with DR4 positivity and erosive joint disease) - however anti-CCP is only detected in about 2% of other types of JIA
      • anti-CCP has also been reported in 8-10% of patients with psoriatic arthritis - again associated with severe joint damage
      • anti-CCP occurs in approximately 7% of patients with primary Sjögren's, often at high titre - however not necessarily associated with erosive joint disease.
      • there is study evidence that anti-CCP predicts RA in patients presenting with an as yet undifferentiated arthritis
        • in this context anti-CCP has a sensitivity ranging from 45-65% but uniformly high specificity and high predictive value
        • the specificity of anti-CCP for diagnosing RA is higher than rheumatoid factor (2)

Reference:

  1. ARC. Topical Reviews - Rheumatic Diseases: Serological Aids to Early Diagnosis. February 2006.
  2. Nishimura K et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis.Ann Intern Med. 2007;146:797-808

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.